Augmentation Strategies for Patients with Major Depressive Disorder with an Inadequate Response to Antidepressant Monotherapy

1. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from Major Depressive Disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156:1000-6.10.1176/ajp.156.7.1000Search in Google Scholar

2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163:28-40.10.1176/appi.ajp.163.1.28Search in Google Scholar

3. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007;8:67-104.10.1080/15622970701227829Search in Google Scholar

4. Gabos Grecu I. Actualități în terapia depresiilor, Editura University Press, Tîrgu Mureș, 2007, pp. 116-129.Search in Google Scholar

5. Moller HJ. Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. World J Biol Psychiatry. 2008;9:102-14.10.1080/15622970801981606Search in Google Scholar

6. Mulder RT, Frampton CM, Luty SE, Joyce PR. Eighteen months of drug treatment for depression: Predicting relapse and recovery. J Affect Disord. 2009;114:263-70.10.1016/j.jad.2008.08.002Search in Google Scholar

7. Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance, and public health signifi cance of subthreshold depressions. Psychiatr Clin North Am. 2002;25:685-98.10.1016/S0193-953X(02)00026-6Search in Google Scholar

8. McIntyre RS, O'Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry. 2004;49(Suppl 1):10S-16S.Search in Google Scholar

9. Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health policy Econ. 2006;9:87-98.Search in Google Scholar

10. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatmentresistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68:826-831.10.4088/JCP.v68n060217592905Search in Google Scholar

11. McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord. 2003;5(Suppl 2):20-35.10.1111/j.1399-2406.2003.00061.x14700010Search in Google Scholar

12. Adson DE, Kushner MG, Eiben KM, Schulz SC. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety. 2004;19:121-126.10.1002/da.1013715022147Search in Google Scholar

13. Yargic LI, Corapcioglu A, Kocabasoglu N, et al. A prospective randomized single-blind, multicenter trial comparing the effi cacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. Int J Psychiatry Clin Pract. 2004;8(4):205-211.10.1080/1365150041000572024930548Search in Google Scholar

14. McIntyre A, Gendron A, McIntyre A. Quetiapine augmentation of SSRIs/ SNRIs in major depression with anxiety. 2006 in Poster presented at: American Psychiatric Association annual meeting, Toronto, Ontario.Search in Google Scholar

15. Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2010;127(1-3):19-30.10.1016/j.jad.2010.08.03220884063Search in Google Scholar